Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2394Neoplasms 1813Carcinoma, Non-Small-Cell Lung 1596Prostatic Neoplasms 1296Colorectal Neoplasms 1138Lung Neoplasms 981Neoplasm Metastasis 830Multiple Myeloma 791Leukemia, Myeloid, Acute 767Ovarian Neoplasms 674Pancreatic Neoplasms 661Melanoma 659Squamous Cell Carcinoma of Head and Neck 584Carcinoma, Hepatocellular 566Recurrence 562Brain Neoplasms 526Glioblastoma 512Head and Neck Neoplasms 500Stomach Neoplasms 497Triple Negative Breast Neoplasms 464Lymphoma 453Uterine Cervical Neoplasms 449Carcinoma, Renal Cell 423Precursor Cell Lymphoblastic Leukemia-Lymphoma 410Lymphoma, Non-Hodgkin 388Endometrial Neoplasms 381Sarcoma 368Lymphoma, Follicular 356Urinary Bladder Neoplasms 354Hematologic Neoplasms 351

Interventions

pembrolizumab 1Taxes 1Sirolimus 1Panitumumab 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Erythema × 1 year × Clear all
NCT02876107 2026-04-15

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
42 enrolled
Breast

Breast Neoplasms, Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02411656 2026-01-23

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
71 enrolled 11 charts
Breast

Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03363763 2025-12-01

Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

Aucta Pharmaceuticals, Inc

Phase 2 Terminated
24 enrolled 11 charts

Erythema, Exanthema, Fibroma, Tuberous Sclerosis, Facies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡